Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G
On March 5, 2025, Denali Therapeutics ( DNLI) Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment ...
Denali Therapeutics price target lowered to $35 from $38 at B. Riley
B. Riley lowered the firm’s price target on Denali Therapeutics (DNLI) to $35 from $38 and keeps a Buy rating on the shares following the Q4 ...
Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?
We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...
Q1 Earnings Estimate for DNLI Issued By HC Wainwright
Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Denali Therapeutics in a ...
Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low Following Analyst Downgrade
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) hit a new 52-week low on Tuesday after Oppenheimer lowered their price target on the stock from $50.00 to $42.00. Oppenheimer currently has an ...
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for ...
Nasdaq2d
Denali Therapeutics Enters Oversold Territory (DNLI)
In trading on Monday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $15.745 per share.